Trial results

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

NCT06191848 on ClinicalTrials.gov · last registry update 2026-10-13

An unusually large phase 4: 352 participants, more than double the 75 typical for the stage. Due to report May 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Percentage of patients who undergo knee replacement in the target joint. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P4

Drug

tirzepatide

Mounjaro, Zepbound

Sponsor

University of Melbourne

Sponsor type

Other

Enrollment

352

Started

2024-11-19

Primary completion

2027-05 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percentage of patients who undergo knee replacement in the target joint

Conditions studied

Obesity · Knee Osteoarthritis · Osteoarthritis, Knee

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.